Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 126 participants.

Also called NCT07255820

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 126 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07255820
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07255820. Randomized; no masking; primary purpose treatment. Start 2026-01-01 (actual); primary completion 2026-03-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol
Condition
Type 2 Diabetes Mellitus
Condition
Hypercholesterolemia / Elevated LDL Cholesterol
Intervention (Drug)
Rosuvastatin + Ezetimibe
Intervention (Drug)
Bempedoic Acid + Ezetimibe
Intervention (Drug)
Rosuvastatin + Ezetimibe + Bempedoic Acid
Lead sponsor
Bahria University (class: other)

Record details

Record id
cardio:ct-nct07255820
Content hash
97882f5701bcab64d9407c41f2d9a8cd898a0dfb77f2a3ff4d3ce7c73d165689